• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ultragenyx Pharmaceu (NQ: RARE )

    44.75 -2.89 (-6.07%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ultragenyx Pharmaceu

    < Previous 1 2 3 4 5 6 7 8 Next >
    Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    The Latest Analyst Ratings For Ultragenyx Pharmaceutical
    Via Benzinga
    Earnings Scheduled For February 15, 2024
    Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
    Via Benzinga
    Preview: Ultragenyx Pharmaceutical's Earnings
    Via Benzinga
    Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    4 Analysts Have This To Say About Ultragenyx Pharmaceutical
    Via Benzinga
    Expert Ratings for Ultragenyx Pharmaceutical
    Via Benzinga
    Analyst Ratings for Ultragenyx Pharmaceutical
    Via Benzinga
    Earnings Outlook For Ultragenyx Pharmaceutical
    Via Benzinga
    Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
    The latest data from the pivotal Transpher A and long-term follow-up studies will be presented at WORLDSymposium™ 2024 
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
    On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83. 
    Via Investor's Business Daily
    Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
    Data from at least 20 patients enrolled in dose expansion cohorts anticipated in the first half of 2024 
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
    On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81. 
    Via Investor's Business Daily
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
    For the first time, paediatric patients aged 5-11 years with HoFH in the EU have access to a first-in-class medicine to treat an ultrarare, inherited form of high cholesterol 
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx to Participate at Investor Conferences in November
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx to Participate in the Jefferies London Healthcare Conference
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Ultragenyx Pharmaceutical Inc.
    Via GlobeNewswire
    Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Gainers 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.